Monday, March 5, 2012

Premium for DPP-IV's in Japan from April, and major price cuts for Pfizer Japan and Roche

Korosho has indicated from April onwards a number of DPP-IV's (alogliptin and linagliptin) will be repriced to include a premium of new drug development. Besides DPP-IV, GLP-1's ( liraglutide, Byetta), Herceptin (trastuzumab), Glivec(imatinib), Halaven (eribulin), Memary (memantine) and Exelon Patch (rivastagamine) will also be eligible for premium. 

Because of the premium (at max would be 5.14%), about 77% of the 702 eligible products would return to the pre-revision NHI prices

Thirty-two products, which would include Alzheimer treatment - Aricept and the diabetes treatment Amaryl (glimepiride) will not be eligible for the premium due to the listing of generics or length of time on the NHI price list (15 years or more). Aricept price would come down by 16.7-16.8% ( ~12.5 NHI price reduction and the rest is due to return of premium because of entry of generics). Pfizer Japan's Lyrica price would be cut 25% due to market expansion within two years of launch.

3 drugs - Nesp (darbepoetin alfa), the ovulation-inducing agent Gonalef (follitropin alfa), and the allergic rhinitis treatment Baynas (ramatroban). will also not be granted premium because of higher than average discrepancies between NHI prices and average market prices.


MAJOR PRICE REDUCTIONS - MARKET EXPANSION

  1. 14.9-15.0% - Celecox (celecoxib)
  2. 12.4-12.5% for Artist (carvedilol) and Maintate (bisoprolol)
  3. 16.2% for the anticancer agents Nexavar (sorafenib) and Sutent (sunitinib)
  4. 15.0% for the antiviral agents Valtrex (valacyclovir) and Famvir (famciclovir),
  5. 15.0% for the treatment of bone metastasis in malignancy Zometa (zoledronic acid), 
  6. 15.0% for the anticancer agent Elplat (oxaliplatin), 
  7. 25.0% for the rheumatoid arthritis treatment Actemra (tocilizumab)
  8. 25.0% for Alimta (pemetrexed; two products) 
  9. 8.8% for Avastin (bevacizumab; two products)
PRODUCTS ELIGIBLE FOR SPECIAL PRICE REDUCTIONS - BY VIRTUE OF GENERIC ENTRY (6%)


  1. Lipitor (atorvastatin)
  2. Acots (pioglitazone)
  3. Pariet (Rabeprazole)
ADHOC PRICE REDUCTIONS (0.86%) FOR COMBINATIONS


  1. Caduet (amlodipine + atorvastatin), 
  2. Metact (pioglitazone + metformin), 
  3. Sonias (pioglitazone + glimepiride) 
  4. Liovel (alogliptin + pioglitazone)